Group 1 - The company, Paige Biopharmaceutical-B (02565.HK), plans to globally offer 19.2835 million H-shares, with 1.9285 million shares for sale in Hong Kong and 17.355 million shares for international sale, with the offering period from May 19 to May 22, 2025, at a price of HKD 15.60 per share [1] - The company focuses on innovative therapies for chronic diseases, particularly in the metabolic disorder field, having developed a core product and five candidate products targeting common metabolic diseases such as Type 2 Diabetes Mellitus (T2DM) and obesity [2] - The core product, PB-119, is a long-acting GLP-1 receptor agonist nearing commercialization, showing benefits in blood sugar control and cardiovascular health, with its New Drug Application (NDA) accepted by the National Medical Products Administration in September 2023 [2] Group 2 - The company has signed cornerstone investment agreements, with cornerstone investors agreeing to purchase 12.692 million shares at the offering price, representing approximately 65.82% of the total shares offered [3] - Estimated net proceeds from the global offering are approximately HKD 231.8 million, with intended uses including 50.2% for commercialization and indication expansion of PB-119, 34.5% for further development of PB-718, and 9.0% for general corporate purposes [3]
派格生物医药-B(02565.HK)预计5月27日上市 益泽康瑞作为基石
Ge Long Hui·2025-05-18 23:06